Transthyretin Amyloid Cardiomyopathy Therapeutics Market Set to Record Exponential Growth by 2027 – SocioHerald
Transthyretin Amyloid Cardiomyopathy Therapeutics Market Set to Record Exponential Growth by 2027 – SocioHerald
Transthyretin amyloid cardiomyopathy is Transthyretin Amyloid Cardiomyopathy a inherited slowly progressive disease, the most common (V122I) is seen predominantly individuals African descent. There are three types amyloid cardiomyopathy: light-chain wild-type amyloidosis. All three forms amyloid cardiomyopathy are progressive fatal. For patients wild-type amyloidosis cardiomyopathy mutant amyloidosis cardiomyopathy.
Multiple presentations on the long-term efficacy and safety of TEGSEDI® (inotersen) in patients with polyneuropathy caused by hATTR Amyloidosis Topline data results to be presented from the Phase 1 study of AKCEA-TTR-L for the treatment of Transthyretin Amyloidosis (TTR) BOSTON and CARLSBAD, Calif. , Aug. 29, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the NEURO-TTR open-label study along with data from the AKCEA-TTR-L amyloidosis heart program and additional clinical presentations on the efficacy and safety profile of TEGSEDI will be presented at the 2nd European ATTR Amyloidosis Alliance Meeting in Berlin, Germany, September 2-3, 2019. The Phase 1 data, along with data on diagnosing Transthyretin Amyloidosis, will be presented at the 23rd Annual Heart Failure Society of America Scientific Meeting in Philadelphia, September 14-19, 2019 Akcea will have an on-site presence at the meeting at booth #7 where attendees can learn more about TEGSEDI and hATTR amyloidosis with polyneuropathy.
Transthyretin amyloidosis is a rare fatal disease Transthyretin Amyloidosis Treatment that destroys nerve cells controlling various functions. The symptoms disease are similar those many other Moreover, timely symptom and treatment is important. amyloidosis is caused due misfolding (TTR) protein, movement, Akcea and Ionis inhibiting ability pump blood body.
Comments
Post a Comment